- FTC Files Amicus Brief in Bystolic Antitrust Litigation Supporting Competition in the Hypertension Drug Market ( )
- U.S. Court of Appeals for the Fifth Circuit Upholds FTC’s Opinion against Generic Pharmaceutical Company Impax Laboratories, LLC ( )
- FTC Again Charges Endo and Impax with Illegally Preventing Competition in U.S. Market for Oxymorphone ER ( )
- FTC Staff Issues FY 2017 Report on Branded Drug Firms' Patent Settlements with Generic Competitors ( )
- Pharmaceutical Agreement Filing Procedures Updated ( )
- FTC Staff Issues FY 2016 Report on Branded Drug Firms’ Patent Settlements with Generic Competitors ( )
- FTC Concludes that Impax Entered into Illegal Pay-for-Delay Agreement ( )
- Last Remaining Defendant Settles FTC Suit that Led to Landmark Supreme Court Ruling on Drug Company “Reverse Payments†( )
- FTC Enters Global Settlement to Resolve Reverse-Payment Charges against Teva ( )
- FTC Amicus Brief Urges Â鶹´«Ã½ District Court Not to Categorically Exempt Hatch Waxman Suits from Antitrust Scrutiny as Potential Sham Litigations ( )
- Administrative Law Judge Dismisses FTC Antitrust Complaint against Generic Pharmaceutical Company Impax Laboratories, Inc. ( )
- FTC to Hold Workshop on Examining Competition Issues Related to Prescription Drug Markets ( )
- FTC Staff Issues FY 2015 Report on Branded Drug Firms’ Patent Settlements with Generic Competitors ( )
- FTC Announces Agenda for November 8 Workshop on Examining Competition Issues Related to Prescription Drug Markets ( )
- FTC to Conduct Workshop on November 8, Examining Competition Issues Related to Prescription Drug Markets ( )
- FTC Testifies before House Judiciary Committee’s Subcommittee on Regulatory Reform, Commercial and Antitrust Law about Antitrust Concerns and the FDA Approval Process ( )
- Â鶹´«Ã½ Trade Commission Approves Appointment of Monitor in Pay-for-Delay Case against Endo Pharmaceuticals Inc. ( )
- FTC Sues Endo Pharmaceuticals Inc. and Others for Illegally Blocking Lower-Cost Generic Versions of the Branded Drugs Opana ER and Lidoderm ( )
- FTC Report on Drug Patent Settlements Shows Potential Pay-for-Delay Deals Decreased Substantially in the First Year Since Supreme Court’s Actavis Decision ( )
- FTC Settlement of Cephalon Pay for Delay Case Ensures $1.2 Billion in Ill-Gotten Gains Relinquished; Refunds Will Go To Purchasers Affected By Anticompetitive Tactics ( )
- FTC Staff Issues FY 2013 Report on Branded Drug Firms’ Patent Settlements with Generic Competitors ( )
- FTC Chairwoman Ramirez Testifies Before House Judiciary Subcommittee on Agency’s Â鶹´«Ã½ of U.S. Antitrust Laws to Promote Competition and Protect Consumers ( )
- FTC Submits Proposed Amicus Brief Concerning “No-Authorized-Generic†Commitments in Drug Companies’ Patent Settlements ( )
- FTC: Recent Supreme Court Decision Puts Agency in Stronger Position to Protect Consumers From Anticompetitive Pay-for-Delay Drug Settlements ( )
- Statement of FTC Chairwoman Edith Ramirez on the U.S. Supreme Court's Decision in FTC v. Actavis, Inc. ( )
- FTC Chairwoman Releases 2012-2013 Annual Highlights ( )
- FTC Study: In FY 2012, Branded Drug Firms Significantly Increased theUse of Potential Pay-for-Delay Settlements to Keep Generic Competitors off the Market ( )
- FTC Testifies Before House Judiciary Subcommittee on Agency's Work to Promote Competition and Benefit Consumers ( )
- FTC Files Amicus Brief in Support of Rehearing of Ciprofloxacin "Pay-for-Delay" Case; FTC Approves Final Rule to Inform Consumers About Deposit Institutions That Lack Â鶹´«Ã½ Deposit Insurance ( )
- Statement by FTC Chairman Jon Leibowitz Regarding Todays Decision by the U.S. Court of Appeals for the Second Circuit in the Ciprofloxacin "Pay-for-Delay" Case ( )
The .gov means it’s official.
Â鶹´«Ã½ government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.
The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.